Our own findings using a much larger dataset are therefore important in providing reassurance that BBs, ACE inhibitors/ARBs and CCBs do not worsen survival outcomes in patients with breast cancer and support their use when necessary. The gene discussed is ACE; the disease is breast carcinoma.